The article discusses the potential of combining antiangiogenic therapies with immunotherapies to enhance cancer treatment. Vascular abnormalities, driven by elevated levels of proangiogenic factors like VEGF and ANG2, facilitate immune evasion and tumor progression. Antiangiogenic agents can normalize these abnormal blood vessels, improving the infiltration of immune cells and converting the immunosuppressive tumor microenvironment (TME) into an immunostimulatory one. This normalization process is crucial for enhancing the effectiveness of immunotherapy, particularly immune checkpoint blockade (ICB). The authors highlight the reciprocal regulation between vascular normalization and immune responses, suggesting that combining antiangiogenic and immunotherapies might increase treatment efficacy and reduce adverse effects. They also discuss the challenges and opportunities in this approach, including the need for optimizing dosing and sequencing of treatments to avoid excessive vessel pruning and ensure effective normalization. The article concludes by emphasizing the importance of further research to understand the complex interactions between antiangiogenic and immunotherapies, and to develop strategies that can improve patient outcomes.The article discusses the potential of combining antiangiogenic therapies with immunotherapies to enhance cancer treatment. Vascular abnormalities, driven by elevated levels of proangiogenic factors like VEGF and ANG2, facilitate immune evasion and tumor progression. Antiangiogenic agents can normalize these abnormal blood vessels, improving the infiltration of immune cells and converting the immunosuppressive tumor microenvironment (TME) into an immunostimulatory one. This normalization process is crucial for enhancing the effectiveness of immunotherapy, particularly immune checkpoint blockade (ICB). The authors highlight the reciprocal regulation between vascular normalization and immune responses, suggesting that combining antiangiogenic and immunotherapies might increase treatment efficacy and reduce adverse effects. They also discuss the challenges and opportunities in this approach, including the need for optimizing dosing and sequencing of treatments to avoid excessive vessel pruning and ensure effective normalization. The article concludes by emphasizing the importance of further research to understand the complex interactions between antiangiogenic and immunotherapies, and to develop strategies that can improve patient outcomes.